Solventum amends purification & filtration sale to Thermo Fisher; consideration reduced to ~$4.0B

Solventum Corp

Amended agreement on June 25, 2025 excludes drinking water filtration business; cash consideration cut from $4.1B to ~$4.0B.
Pro forma net income for H1 2025: $86M (vs historical $227M) after removal of business and transaction adjustments.
Pro forma net income for FY2024: $1,677M (vs historical $479M) including $1.56B estimated pre-tax gain on sale.
Net cash proceeds estimated at $3.89B after costs, working capital, and debt adjustments; proceeds to be used for debt paydown.
Transaction expected to close with customary adjustments; ~$98M non-current assets remain due to delayed transfers in certain jurisdictions.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.